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Abstract: Spray-drying is an increasingly popular technology for the production of amorphous solid
dispersions (ASDs) in the pharmaceutical industry that is used in the early evaluation and industrial
production of formulations. Efficient screening of ASD in the earliest phase of drug development
is therefore critical. A novel miniaturized atomization equipment for screening spray-dried solid
dispersions (SDSDs) in early formulation and process development was developed. An in-depth
comparison between the equipment/process parameters and performance of our novel screening
device and a laboratory Büchi B290 mini spray-dryer was performed. Equipment qualification
was conducted by comparing the particle/powder attributes, i.e., miscibility/solid state, residual
solvent, and morphological properties of binary SDSDs of itraconazole prepared at both screening
and laboratory scales. The operating mode of the miniaturized device was able to reproduce similar
process conditions/parameters (e.g., outlet temperature (Tout)) and to provide particles with similar
drug–polymer miscibility and morphology as laboratory-scale SDSDs. These findings confirm that
the design and operation of this novel screening equipment mimic the microscale evaporation
mechanism of a larger spray-dryer. The miniaturized spray-dryer was therefore able to provide
a rational prediction of adequate polymer and drug loading (DL) for SDSD development while
reducing active pharmaceutical ingredient (API) consumption by a factor of 120 and cycle time by a
factor of 4.
Keywords: amorphous solid dispersions; spray-dryer; screening; miniaturization; downscaling;
miscibility; polymers
1. Introduction
Spray-drying is a widely used process in the pharmaceutical industry to transform a solution,
suspension, or emulsion into a powder [1,2]. The operation mode of spray-drying can be described by
four steps: atomization of the feed solution into fine droplets, contact with hot drying gas, fast solvent
evaporation, and separation of dried particles from drying gas [3]. Droplet-air contact via a cocurrent
configuration where an atomized solution and drying gas are flowing in the same direction is the
most prevalent method in the pharmaceutical industry. This configuration allows for the processing
of heat-sensitive compounds because exposure to high temperatures is very limited due to solvent
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evaporation cooling [4]. Additionally, spray-drying is a continuous process that offers the advantages
of tailoring both particle attributes (e.g., particle size, specific surface area, morphology, and residual
solvent) and powder properties (e.g., flowability, compressibility, and bulk density) [5,6].
The use of spray-drying has been particularly suitable for the preparation of amorphous solid
dispersions (ASDs) at the industrial scale [7]. This can be explained on the basis that the rapid solvent
evaporation that occurs during the process minimizes the time window for phase separation and
recrystallization and favors the formation of an amorphous system [8]. Manufacturing of stable
ASDs is currently one of the most investigated formulation strategies in drug delivery design to
overcome solubility challenges of class II and class IV drugs (according to the biopharmaceutics
classification system) [9]. The term ASD refers to the formulation technique which consists of the drug
amorphization and its dispersion into a hydrophilic polymeric (amorphous) carrier [10]. Nevertheless,
inappropriate carrier selection, drug loading (DL), and process conditions/methods can engender
phase separation/drug recrystallization after processing that would lead to a reduction in ASD
performance [11,12]. In contrast, the formation of a single amorphous phase system, also referred
to as “glass solution”, where the amorphous drug is molecularly dispersed into the polymeric chain
represents the most favorable ASD system in terms of physical stability and solubility enhancement [13].
Spray-drying is a scalable process that finds application at various stages of active pharmaceutical
ingredient (API) development, from the early evaluation of the formulation to pilot size scale-up
and production at a further industrial scale where batches of up to several tons per day can be
achieved. Therefore, the prediction of the properties and performance of spray-dried solid dispersions
(SDSDs) prepared during pilot/industrial production is of major interest from the earliest stages of
drug development. In this regard, several small-scale screening methods such as film casting, quench
cooling, or spin coating have been developed to predict the properties of SDSDs and therefore select the
appropriate carrier and DL for the manufacturing of robust SDSDs [14,15]. Although these standard
methodologies only require a minimal drug amount, their lack of correlation with the operating
conditions of regular spray-drying limits their applicability and usefulness [16,17]. Moreover, although
the application of laboratory spray-dryers can be particularly suitable to support preclinical to early
stage clinical activities, their use remains limited during screening phases when a very limited amount
of API is available for experimental work [18].
Therefore, given that spray-drying is a complex technology where the interplay of process
parameters and process conditions (e.g., inlet temperature, drying airflow, feed rate, atomizing airflow,
and nozzle configuration) is known to influence the droplet/particle formation [19,20] and thereby
the particle/powder properties [21], there is a necessity to develop a novel small-scale screening
system that would be representative of the operating mode and the process conditions of a regular
spray-dryer. Efforts to miniaturize and mimic existing manufacturing processes are currently a hot
topic in the pharmaceutical industry [22]. As such, the objective of this paper was to develop a robust,
cost-effective, and efficient miniaturized screening device mimicking a standard laboratory spray-dryer
to provide an accurate prediction of SDSDs properties. The device’s design was aimed to respect
the formulation development constraints in a preformulation context such as reduced time and very
limited API availability for screening purposes.
In this paper, first, the operational equipment parameters and design of our miniaturized device
was compared to laboratory-scale Büchi B290 mini spray-dryer. Then, the performance of both
equipment in terms of API consumption, production rate, yield, and output parameters were compared
in order to assess their capability to operate in a screening environment. Finally, the qualification of
this novel screening device was conducted with the production of 20:80, 40:60, 60:40, and 80:20 (w/w)
itraconazole binary ASDs prepared with a set of polymers commonly tested during preformulation
screening phases (e.g., HPMCP HP50, HPMCAS-LF, PVPVA, PVPK30, Soluplus, Eudragit L100, and
Eudragit L100-55). Particle/powder attributes of itraconazole SDSDs generated at both screening
and laboratory scales were compared in terms of morphological properties, solid state, drug–polymer
miscibility, and moisture/residual solvent content. The investigated spray-dried material attributes
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would allow insight on how the process conditions and design of both systems impact the droplet
evaporation kinetic and particle formation process of SDSDs.
2. Materials and Methods
2.1. Materials
Crystalline itraconazole was purchased from SRIS Pharmaceuticals (Hyderabad, India).
Hydroxypropylmethylcellulose phthalate (HPMCP HP50) and hydroxypropylmethylcellulose
acetate succinate fine grade (HPMCAS-LF) were obtained from Shin-Etsu (Tokyo, Japan).
Polyvinylpyrrolidone (PVPK30) was purchased from VWR (Radnor, PA, USA), copolymer of
N-vinyl-2-pyrrolidone and vinyl acetate (PVPVA) was obtained from Ashland (Covington, KY, USA),
and copolymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer
(Soluplus) was donated by BASF (Ludwigshafen am Rhein, Germany). Copolymer of methacrylic acid
and methyl methacrylate 1:1 (Eudragit L100) and copolymer of methacrylic acid and ethyl acrylate
copolymer 1:1 (Eudragit L100-55) were donated by Evonik (Essen, Germany). The solvents used were
of analytical or HPLC grade.
2.2. Methods
2.2.1. Design of the Novel Miniaturized Atomization Device
The atomization of the feed solution was achieved by using a bifluid 0.15-mm Infinity Two in One
airbrush nozzle (Harder & Steenbeck, Norderstedt, Germany). The airbrush used here is commonly
used for painting applications and allows the generation of a fine spray. The air nozzle pressure was
fixed at 1.5 bars to disperse the feed solution and create a spray. Contrary to a laboratory spray-dryer,
where a peristaltic pump is generally used to transfer the feed solution to the nozzle, in the current
miniaturized design, the relatively low volume of feed solution (0.25–1 mL) was spread into the
reservoir of the airbrush. In this configuration, the feed solution was directly available to the nozzle,
which allowed avoiding the presence of dead volume as it occurs in the tubing of a standard pump and
therefore minimized the loss of material during the process. The amount of feed solution brought to
the nozzle was manually controlled by the operator by adjusting the amplitude of the airbrush needle.
About 1 mL of feed solution was gradually atomized in a time period of 30 s. The same procedure was
reproduced during all experiments.
As shown in Figure 1, the proposed miniaturized equipment was comprised of seven parts. Part I
represented the inox holder on top of the device in which the nozzle was disposed during processing.
Part II was an inox tubing that serves as an inlet for drying air supply. Droplet drying was achieved
using a drying airflow rate of 20 L/min at 100 ◦C generated using an Aoyue int 852 SMD rework
station (Aoyue, Zhongshan, China). Part III was a 3D-printed system which ensured sealing on top of
the system and favors the droplet-air contact through a cocurrent configuration. Part IV consisted of
bottom sawed glass tube of 15 cm (VWR, Heverlee, Belgium) and was used as the drying chamber of
the system in which solvent evaporation and particle formation took place. Once drying of the droplets
was achieved, the flow of dried particles was transported to the bottom of the drying chamber and
passed through a 3D-printed funnel (Part V). Separation of dried particles from the exhaust airflow
was achieved in contact with Part VI, typically a standard aluminium differential scanning calorimetry
(DSC) pan (TA Instruments, Leatherhead, UK) attached on the center of a 3D-printed pan holder (Part
VII). Powder was collected into Part VI while air was removed from the interstices of Part VII and
evacuated at the bottom of the chamber. Regarding safety and cleaning considerations, the materials
chosen in the equipment design were resistant to many organic solvents, cleaning agents, and were
compatible with the excipients and drug used.
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powder collection in differential scanning calorimetry (DSC) aluminium pan for powder collection; Part 
VII: perforated 3D-printed DSC pan holder (ABS). 
2.2.2. Performance Qualification of the Novel Device 
In order to assess the performance of the novel equipment, binary ASDs of itraconazole were 
produced at 20%, 40%, 60%, and 80% (w/w) DL with a large range of polymers (HPMCP HP50, HPMCAS-
LF, PVPVA, PVPK30, Soluplus, Eudragit L100, and Eudragit L100-55) commonly used in the screening 
phases of ASD in the pharmaceutical industry. Drug and polymer solutions were prepared in a binary 
solvent mixture of Dichloromethane (DCM)/Ethanol (EtOH) 2:1 (v/v) at 5% (w/v) to be representative of 
feed solutions commonly used at laboratory scale. After processing, a minimum amount of 2 mg of 
powder was collected to ensure that sufficient material was available for analytical characterization. 
2.2.3. Manufacturing Method of Reference—Spray-Dryer 
Productions of binary SDSD were conducted using the laboratory-scale Büchi B290 mini spray-
dryer (Büchi Labortechnik AG, Flawil, Switzerland). The inlet temperature was fixed at 65 °C and the 
drying airflow rate at 35 m3/h. Feed solution atomization was performed using a 0.7-mm bifluid 
nozzle and an atomizing airflow of 9 L/min while the solution feed rate was maintained at 4 mL/min. 
During the process, the system was operating in a closed recycling loop configuration. 
2.2.4. Operational and Performance Equipment Parameters 
Yield 
Yield (%) was calculated as the ratio between the amount of particles collected in the DSC pan 
or in the collector at miniaturized and laboratory scale, respectively, and the total amount of solid 
dissolved in the feed solution. 
Equipment Parameters Including Dimensionless Parameter 
 Atomizing-airflow-to-liquid-feed-flow-rate ratio was calculated using both our miniaturized 
device and laboratory-scale Büchi B290 mini spray-dryer. Density (ρ) values of DCM (ρDCM(25 °C) 
= 1.33 g/mL), air (ρair(25 °C-1013.25 mbar) = 1.184 kg/m3), and nitrogen (ρN2 (25 °C-1013.25 mbar) = 1.145 kg/m3) 
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powder collection in differential scanning calorimetry (DSC) aluminium pan for powder collection;
Part VII: perforated 3D-printed DSC pan holder (ABS).
2.2.2. Performance Qualification of the Novel Device
In order to assess the performance of the novel equipment, binary ASDs of itraconazole were
produced at 20%, 40%, 60%, and 80% (w/w) DL with a large range of polymers (HPMCP HP50,
HPMCAS-LF, PVPVA, PVPK30, Soluplus, Eudragit L100, and Eudragit L100-55) commonly used
in the scr ening phases of ASD in he pharma eutical industry. Drug and polymer soluti ns were
prepared in a binary solvent mixture of Dichloromethane (DCM)/Ethanol (EtOH) 2:1 (v/v) at 5%
(w/v) to be representative of feed solutions commonly used at laboratory scale. After processing, a
minimum amount of 2 mg of powder was collected to ensure that sufficient material was available for
analytical characterization.
2.2.3. Manufacturing Method of Reference—Spray-Dryer
Productions of binary SDSD were co ducted using the laboratory-scale Büchi B290 mini
spray-dryer (Büchi Labortechnik AG, Flawil, Switzerland). The inlet temperature was fixed at 65 ◦C
and the drying airflow rate at 35 m3/h. Feed solution atomization was performed using a 0.7-mm
bifluid nozzle and an atomizing airflow of 9 L/min while the solution feed rate was maintained at
4 mL/min. During the process, the system was operating in a closed recycling loop configuration.
2.2.4. Operational and Performance Equipment Parameters
Yield
Yield (%) was calcu ated as the ratio between he amount of particles collected in the DSC pan
or in the collector at mini turized and laboratory sc le, respectively, and the total amount of solid
dissolved in the feed solution.
Equipment Parameters Including Dimensionless Parameter
• Atomizing-airflow-to-liquid-feed-flow-rate ratio was calculated using both our miniaturized
device and laboratory-scale Büchi B290 mini spray-dryer. Density (ρ) values of DCM
(ρDCM(25 ◦C) = 1.33 g/mL), air (ρair(25 ◦C-1013.25 mbar) = 1.184 kg/m3), and nitrogen (ρN2 (25 ◦C-1013.25 mbar)
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= 1.145 kg/m3) were used to convert the volumetric flow rate of feed solution and atomizing airflow
(mL/min and L/min, respectively) into mass flow rate (g/min). This dimensionless parameter allows
correlating the atomization conditions to the droplet size and comparing the process atomization
characteristics of spray-drying operating at different scales [23,24].
• The ratio of the equipment volume to the minimum amount of API used when processing was
calculated at both scales, respectively. Such a calculation allows estimation of the material loss
on the glass wall’s drying chamber for different manufacturing processes. The volume of the
equipment was approximated by considering the geometry of the drying chamber equivalent to
a cylinder.
Residence Time
The residence time of spray-dried particles in the miniaturized system and the Büchi B290 mini
spray-dryer was roughly estimated as seen in Equation (1):
tr =
Vc
QDA
(1)
where tr is the droplets’ residence time, Vc is the volume of the drying chamber, and QDA is the
volumetric drying gas airflow. The main assumption is that the droplets’ residence time approximates
the air residence time in the chamber. Calculation of a volume cylinder was used to estimate the
volume of the drying chamber.
2.2.5. Powder Characterization
Modulated Differential Scanning Calorimetry
Modulated differential scanning calorimetry (mDSC) analyses were conducted using TA
Instruments Q1000 calorimeter (TA Instruments, Leatherhead, UK). About 2–4 mg of powder was
analyzed in closed standard aluminium pans (TA Instruments, Leatherhead, UK). Samples were
heated from −50 to 210 ◦C at 2 ◦C/min combined with a modulation of ±1 ◦C and a period of 40 s.
The thermograms were collected and data were processed using Universal Analysis 2000 software
(TA Instruments, Leatherhead, UK). Glass transition temperature (Tg) was evaluated in the reverse heat
flow signal, while melting and crystallization events were both examined in the total and nonreverse
heat flow signals.
Thermogravimetric Analysis
Thermogravimetric analysis (TGA) experiments were conducted on a TGA Q500 (TA Instruments,
Leatherhead, UK). Spray-dried powder was heated from 25 to 300 ◦C at a constant heating rate of
2 ◦C/min. The chamber was swept by a 100 mL/min flow rate of dry nitrogen. Data were processed
using Universal Analysis 2000 software (TA Instruments, Leatherhead, UK).
X-Ray Powder Diffraction
X-ray powder diffraction (XRPD) experiments were performed on an X Bruker AXS D8 Advance
(Bruker, Karlsruhe, Germany). Each sample was dropped on the center of a silicium monocrystal
holder and analyzed at a scan speed of 2.5 s/step and a step size of 0.02◦ between 4.5◦ and
30◦. The diffractograms representing the intensity as a function of 2θ were processed using Eva
DIFFRAC-SUITE software (Bruker, Karlsruhe, Germany).
Scanning Electron Microscopy
Scanning electron microscopy (SEM) observations were performed using the JEOL JSM-IT300 SEM
(JEOL, Tokyo, Japan) to characterize the morphology of the spray-dried particles. An aluminium stud
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with a conductive double-sided carbon adhesive tape was used for sample preparation. Observations
were made at an accelerating voltage of 5 kV in high-vacuum mode. The data treatment and picture
collection was realized using JEOL IT300 Operation software (JEOL, Tokyo, Japan).
3. Results and Discussion
3.1. Operational Equipment Parameters and Its Comparison to Laboratory-Scale Büchi B290 Mini Spray-Dryer
Prior to the development of the miniaturized screening device, design criteria and user
requirements specifications were established to design a system that mimics the operating mode
of a spray-dryer and that allows the adjustment of process and formulation variables in the range
of values typically found at laboratory/pilot scale. A later stage comparison with large-scale (e.g.,
pilot/industrial) equipment would be undertaken to finalize the equipment evaluation. Table 1
provides a comparison of the operating modes and process conditions between the miniaturized
device and the laboratory-scale Büchi B290 mini spray-dryer in terms of feed solution properties,
equipment configuration, drying gas, and atomization process conditions.
Firstly, critical material attributes (CMAs), including solvent choice, concentration, DL, and
selected carriers, were maintained during downscaling. It was demonstrated that the miniaturized
spray-dryer can operate with feed solutions having different properties in terms of viscosity and surface
tension and can produce amorphous material with different Tg values. Secondly the miniaturized
system allows the reproduction of critical process parameters (CPPs), e.g., inlet temperature, atomizing
gas airflow, and feed flow rate, in the range of those of a laboratory-scale dryer, as detailed in Table 1.
A bifluid nozzle was selected in the design of the novel equipment to be representative of droplet
formation that occurs at laboratory scale. In this regard, atomizing-airflow-to-liquid-feed-flow-rate
ratio was calculated using both our miniaturized device and laboratory-scale Büchi B290 mini
spray-dryer. Values of 1.9 and 8.0 were obtained at laboratory and screening scales, respectively.
The impact of applied atomization conditions will be further discussed in the equipment qualification
section. According to Kemp et al. (2013), if the atomizing-gas-to-liquid ratio exceeds 6, a particle
size of 2–3 µm can be generated [25]. However, this dimensionless parameter does not include the
nozzle geometry/diameter, gas velocity, and feed solution concentration that also impacts the particle
size distribution (PSD) in addition [23]. Herein, air was used as a drying and atomizing gas while
nitrogen was generally applied at laboratory scale. Even if the atomizing-gas-to-liquid ratio was not
kept constant during downscaling, the use of dimensionless parameters during scale-up/transfer
procedure offered a first estimate of mechanisms occurring across spray-drying at various scales.
As detailed in Table 1, drying gas airflow was significantly reduced from 580 to 20 L/min during
downscaling. The smaller dimension of the drying chamber at miniaturized scale (15× 2 cm) compared
to laboratory dryer (47 × 15.9 cm) required a reduced drying gas airflow in order to avoid turbulence
within the chamber. Additionally, the miniaturized dimension of the drying chamber was found to
reduce droplets’ residence time: values estimated at around 0.14 and 0.96 s, respectively, were obtained
for the miniaturized equipment and the Büchi B290 mini spray-dryer. This calculation considers a
laminar drying airflow within the chamber which probably deviates to some extent to experimental
conditions. Alternatively, computational fluid dynamics (CFD) simulations have been used to model
the fluid dynamics inside Büchi B290 mini spray-dryer and allowed the estimation of the resident time
under different process conditions [26]. The obtained values confirmed the smaller residence time of
droplets within the chamber at the miniaturized scale, which limited its drying capacity compared to
the larger dryer. In this way, the droplets need to be small enough to ensure they are completely dry
before leaving the system. Based on these considerations, a smaller nozzle diameter (0.15 mm) and an
increased atomizing airflow (18 L/min) were chosen to generate smaller droplets from the nozzle and
to ensure efficient droplet drying at miniaturized scale [27]. Additional experimental trials revealed
that the miniaturized process is appropriate only for organic solvents as it was not able to operate with
aqueous feed solution to ensure the complete drying of the droplets within the chamber.
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Table 1. Comparison of equipment operational parameters, equipment design, and performance between miniaturized atomization device and laboratory-scale Büchi
B290 mini spray-dryer.
Miniaturized Atomization Device Büchi B290 Mini Spray-Dryer
Feed solution
Solvent DCM/EtOH 2:1 (v/v) DCM/EtOH 2:1 (v/v)
Concentration of solutes 5% (w/v) 5% (w/v)
DL 20%–80% (w/w) 20%–80% (w/w)
Volume of feed solution 0.25–1 mL 100 mL
Feed flow rate 2 mL/min 4 mL/min
Equipment configuration
Drying chamber dimension (length × diameter) 15 × 2 cm 47 × 15.9 cm a
Drying chamber surface area 94.2 cm2 b 2.3.103 cm2 b
Drying chamber volume 5.0.10−2 L b 9.3 L b
Recycling loop configuration open closed
Drying gas
Drying gas flow rate 20 L/min 580 L/min
Drying gas Air N2
Heating power 500 W 2300 W a
Inlet temperature 100 ◦C 65 ◦C
Residence time 0.14 s c 0.96 s c
Atomization
Nozzle selection bifluid bifluid
Nozzle diameter 0.15 mm 0.7 mm
Atomization gas flow rate 18 L/min 9 L/min
Atomization gas Air N2
Atomization gas flow rate/Feed flow rate 8.0 c 1.9 c
Particle separation system and powder properties
Particle separation principle DSC pan cyclone
Particle separation selectivity - 2 µm a
Typical PSD obtained ≤10 µm d ≤10 µm d
Equipment performance and output parameters
Minimum sample volume per batch 0.25 mL 30 mL a
Corresponding minimum materials needs per batch 12.5 mg e 1.5 g e
Production rate per hour 4 f 1 f
Typical yield value 15%–50% 65%–90%
Outlet temperature 40 ± 5 ◦C 45 ± 2 ◦C
Drying chamber surface area/min. API used 7.5 × 103 cm2/g b,e 1.5 × 103 cm2/g b,e
a data obtained from literature and technical features of the Büchi B290 mini spray-dryer [28,29], b calculation of the lateral surface and the volume of a cylinder were used to estimate the
surface area and the volume of the drying chamber, respectively, c calculation detailed in Methods section, d data experimentally obtained from SEM observations, e estimation based on
minimum sample volume per batch and feed solution concentration used, f including thermal equilibration within the drying chamber, production, and cleaning of the system.
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3.2. Equipment Performance and Comparison to a Büchi B290 Mini Spray-Dryer
3.2.1. API Consumption, Production Rate, and Yield Obtained
As seen in Table 1, the main benefit of using the miniaturized equipment relies on its capability to
significantly reduce the API amount needed for a production. The use of this novel equipment would
lead to an API saving by a factor of 120. Additionally, a production rate of four samples per hour,
including thermal equilibration within the drying chamber, production, and cleaning of the system,
can be achieved with the proposed device, i.e., production rates are improved fourfold compared to
the laboratory dryer. These two elements confirm the great potential of our miniaturized device to
address formulation development constraints during screening phases when API is scarce and time
for development is very limited.
Equipment performance, including yield evaluation of the spray-dried material, was performed
at both scales. As detailed in Table 1, yield values of up to 50% can be obtained when using our
miniaturized equipment at the milligram scale, while typical yield values obtained at laboratory scale,
i.e., for gram-scale productions, range from 65% to 90%. The lower yield obtained at the miniaturized
scale compared to the laboratory spray-dryer can be explained by the batch size differences produced
at both scales. It is well known that the production of extremely small batch sizes at the milligram scale
leads to a drop in the yield of the spray-dried material [18]. Additionally, the yield variation found
between both manufacturing processes can be also attributed to the higher equipment surface area in
relation to the used material at the miniaturized scale (7.5 × 103 cm2/g) compared to the laboratory
dryer (1.5 × 103 cm2/g). This represents almost a fivefold increase of such parameters at a smaller
scale that translates to an increased risk of having spray-dried material deposit on the wall of the
drying chamber during the process.
Despite a lower yield value at the miniaturized scale, sufficient spray-dried material was collected
for subsequent analytical characterization. Contrary to laboratory-scale equipment, where powder
separation occurs across a cyclone [30], experimental trials revealed that the finetuned system of
powder collection into a DSC pan described in the Methods section allowed for the maximization
of the collection of fine particles generated at the miniaturized scale. This design was found to be
particularly suitable to remove powder handling after processing, facilitate the powder preparation,
and transfer to later analytical characterization. This setup is advantageous in terms of operating,
cleaning, throughput, and cross-contamination.
3.2.2. Outlet Temperature Monitoring
Measurements of outlet temperature (Tout) at the bottom of the drying chamber confirmed the
ability of the novel device to reproduce Tout in the range of values typically used at laboratory scale.
Values of 40 ± 5 ◦C and 45 ± 2 ◦C were measured at screening and laboratory scales, respectively.
Despite the fact that our miniaturized equipment operates at a higher inlet temperature (100 ◦C)
compared to laboratory equipment (65 ◦C), similar Tout values were obtained. This can be explained by
the differences in terms of recycling loop configuration and heat loss among the two processes [31,32].
On the latter point, the smaller dimension of the miniaturized drying chamber is expected to reduce
the heat loss through the glass wall of the chamber compared to laboratory- or pilot-scale dryers. This
last point is confirmed by the calculation of the drying chamber surface area of both investigated
processes, as detailed in Table 1. Surface areas of 94.2 cm2 and 2.3 × 103 cm2 were estimated at the
miniaturized and laboratory scale, respectively.
Tout is often considered as one of the most important CPPs of spray-drying, identified as a key
process parameter to be evaluated during the scale-up procedure [28,33,34]. As Tout represents the
highest temperature encountered by the dried particles during droplet drying [19], a change in Tout
can affect the physical and structural properties of the particles. In this regard, the fact that similar Tout
values were maintained during downscaling ensures a reproducible production process and therefore
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provides consistent product quality. The impact of Tout used at both scales will be further discussed in
the equipment qualification section.
Herein, the relatively low Tout value (approximately 45 ◦C) would allow the production of a large
set of ASDs, including low Tg samples, by reducing the risk of stickiness of the spray-dried amorphous
material to the glass wall [35]. It is important that the development of robust process conditions of
spray-drying takes into account the drying efficiency to reduce the level of residual solvent and to
prevent phase separation while maximizing powder collection [36,37]. As a result, the value of Tout is
often a compromise between these factors [38].
3.3. Equipment Qualification: Comparison of Particle/Powder Attributes of SDSDs Generated from the Two
Scale Manufacturing Processes
3.3.1. Particles’ Morphology
The proposed miniaturized equipment was qualified by producing binary SDSDs of itraconazole
at the milligram scale and comparing the powder/particle properties with respective samples produced
by the laboratory dryer. Characterization of the structural shape of spray-dried particles is of particular
interest as it provides evidence on how solvent evaporation and particles’ formation occur during the
drying process [39]. Since SDSD is a formulation intermediate that needs to be further processed prior
to preclinical or clinical application, powder properties such as bulk density and flowability are critical
quality attributes. These powder attributes are often a linked to the structural and morphological
characteristics of spray-dried particles. In this regard, the morphology of itraconazole 40:60 (w/w)
SDSD particles produced using the novel screening device and the laboratory-scale Büchi B290 mini
spray-dryer was examined by SEM, and images are provided in Figures 2 and 3, respectively.
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As seen in Figure 2, the spray-dried particles of itraconazole ASDs prepared at a smaller scale
display a spherical shape with a shriveled surface for all tested carriers. Additionally, the smallest
particles of itraconazole/PVPVA and itraconazole/PVPK30 40:60 (w/w) SDSDs display a spherical
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shape with a smooth surface (Figure 2a,b). At laboratory scale, particles with similar morphology
were obtained for the respective samples. As seen in Figure 3, spherical particles with a shriveled
surface were found for SDSDs prepared with PVPVA, PVPK30, and HPMCAS-LF (Figure 3a–c), while
spherical particles with a rough surface were found with Eudragit L100-55 SDSD (Figure 3d).
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The fact that SDSDs produced at both screening and laboratory scales were found to have
similarities in morphology can be attributed to a comparable Tout value and similar feed solution
concentrations maintained during downscaling [6]. The morphological structure obtained, i.e., particles
with a spherical shape and shriveled surface, is typical of the spray-drying of pharmaceutical material
with a relatively low feed solution concentration and relatively low Tout. As mentioned in previous
sections, the feed solution concentration was fixed at 5% (w/v), while Tout was measured at around
45 ◦C with both equipment. As feed solution concentration influences the shell thickness formed
in the early phase of droplet drying and Tout directly impacts the droplet drying time, the selected
process conditions increase the time window for shell flexibility and favor the probability of obtaining
shriveled particles [6]. In this regard, several studies have highlighted the influence of Tout on the
particle morphology of spray-dried material in various industrial sectors [40], and powder properties
such as density, morphology, and mechanical strength are directly impacted by the Tout value [41].
Additionally, the fact that itraconazole/Eudragit L100-55 of 40:60 (w/w) solid dispersion display
particles with different morphological properties than other SDSDs generated at laboratory scale can
be attributed to the influence of the carrier used in the blend. This is linked to the fact that mechanical
properties and flexibility of the shell formed early during droplet drying varies according to the
polymer type [6,42].
SEM analysis was also used to provide information regarding the PSD of SDSDs produced at both
scales. As seen in Figures 2 and 3, fine particles with a PSD lower than 10 µm was generated using
both our miniaturized equipment and Büchi B290 mini spray-dryer. This observation is typical for
spray-dried particles generated from a bifluid nozzle, where atomization of the solution is obtained
by the pressure of a compressed carrier gas and generally conducts to the formation of relatively low
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particle sizes [43]. This finding qualifies the choice made in the design of this miniaturized equipment
regarding atomization conditions, especially.
Additional observations in SEM revealed that a fraction of particles generated at a small scale was
found lower than 2 µm (Figure 2a–c), which is below the cyclone efficiency of the laboratory-scale dryer.
In contrast, the proposed design for the screening atomization device does not include a cyclone to
collect the dried particles from the exhaust airflow. As detailed in the Methods section, the spray-dried
material, including the smallest particles (typically in the nanometer size range), is directly sent into
a DSC pan, while for laboratory dryer, these particles are typically carried out of the cyclone by the
air stream. Moreover, the presence of very fine particles collected can be also explained on the basis
that a smaller nozzle diameter (0.15 mm) and higher atomizing gas airflow (18 L/min) have been
used at small scale to ensure efficient drying of the droplets within the chamber. This observation
translates well with the atomizing-airflow-to-liquid-flow-rate ratio calculation summarized in the
previous section, where particle sizes as small as 2–3 µm were expected at the screening scale.
3.3.2. Miscibility and Solid State Properties of SDSDs
First, the solid state of solid dispersions generated at both screening and laboratory scales was
examined using XRPD. Results obtained for 40:60 and 60:40 (w/w) SDSDs are depicted in Figure 4.
All samples produced using our miniaturized equipment were characterized by the presence of an
amorphous halo and the absence of Bragg peaks in XRPD pattern. Similar results were obtained for
the respective reference samples produced with a larger spray-dryer. The fact that all solid dispersions
produced at both scales were characterized as amorphous solids suggests that the selected process
conditions prevent drug recrystallization during the manufacturing process. This finding reinforces
the ability of our miniaturized equipment to manufacture amorphous SDSDs, correlating well with
respective samples produced with the larger dryer.Processes 2018, 6, x FOR PEER REVIEW  13 of 21 
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Additionally, the drug–polymer miscibility of itraconazole ASDs was characterized using mDSC.
Figure 5 displays the mDSC thermograms obtained for 40:60 (w/w) itraconazole SDSDs produced
at both screening and laboratory scales. Glass solutions, depicted by the presence of a single Tg
in the reverse heat flow signal of mDSC, were found for all 40:60 (w/w) ASDs produced from the
two techniques.Process s 2018, 6, x FOR PEER REVIEW  14 of 21 
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The mean Tg values of obtained glass solutions are summarized in Table 2. Similar Tg values were
obtained for all tested drug–polymer combinations. Assessment of Tg properties during ASD screening
is known to provide useful information regarding the physical stability of amorphous system [44].
Again, this confirms the robustness of our miniaturized equipment to gain insight into final properties
of SDSDs.
able 2. Su ary of Tg values and percentage of eight loss of 40:60 ( /w) binary a orphous solid
dispersions ( S s) of itraconazole ge erate at bot scree i g a laboratory scales.
40:60 (w/w) ASDs
Miniaturized Atomization Device Büchi B290 Mini Spray-Dryer
Tg a (◦C) % Weight Loss b Tg a (◦C) % Weight Loss b
itraconazole/HPMCP HP50 100.5 ± 0.1 1.8 99.7 ± 0.9 1.8
itraconazole/HPMCAS-LF 85.4 ± 1.8 1.7 87.4 ± 0.6 1.2
itraconazole/PVPVA 94.2 ± 0.3 4.3 95.9 ± 0.3 4.0
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Table 2. Cont.
40:60 (w/w) ASDs
Miniaturized Atomization Device Büchi B290 Mini Spray-Dryer
Tg a (◦C) % Weight Loss b Tg a (◦C) % Weight Loss b
itraconazole/PVPK30 128.6 ± 0.7 9.0 128.7 ± 1.0 8.6
itraconazole/Soluplus 53.9 ± 1.6 2.8 50.2 ± 1.6 2.3
itraconazole/Eudragit L100 158.8 ± 2.1 3.4 160.2 ± 1.5 3.6
itraconazole/Eudragit L100-55 107.3 ± 1.5 1.9 106.7 ± 0.4 1.5
a mean Tg value obtained from triplicate measurements performed in mDSC, b obtained from TGA analysis.
Similarly, the phase behavior of 60:40 (w/w) itraconazole solid dispersions prepared at the
screening scale was compared to respective samples prepared at the laboratory scale with Büchi B290
mini spray-dryer, as detailed in Figure 6. Regarding both techniques, glass solutions were obtained
with HPMCP HP50, HPMCAS-LF, Eudragit L100, and Eudragit L100-55, exclusively. The thermograms
of samples made with PVPVA, PVPK30, and Soluplus displayed the presence of drug melting in reverse
heat flow signal. More precisely, the drug recrystallization process was identified in the total heat flow
signal (data not shown) and can be interpreted as a sign of ASD instability. Moreover, phase separation
was observed by the presence of multiple Tg values in the reverse heat flow signals of PVPVA and
PVPK30 ASDs. In the case of itraconazole/PVPK30 60:40 (w/w), the Tg of pure glassy itraconazole, its
inherent mesophase endotherms, and a second Tg linked to a polymer rich domain were identified [45].
ASDs identified as an amorphous phase separated system are not the preferred choice, as these systems
are more prone to recrystallization during storage than ideal glass solutions [46].
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HPMCAS-LF (b), PVPVA (c), PVPK30 (d), Soluplus (e), Eudragit L100 (f), and Eudragit L100-55 (g)
produced by the miniaturized screening device and Büchi B290 mini spray-dryer.
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Table 3 summarizes the phase behavior of itraconazole SDSDs at various DLs using both
manufacturing processes. Results obtained with the novel atomization device suggest its robustness
to consistently reproduce the phase behavior of itraconazole SDSDs produced at laboratory scale.
Because the inherent miscibility of SDSD is a direct consequence of droplets drying kinetically during
the spray-drying process, this finding confirms the ability of our novel miniaturized equipment
to reproduce the microscale evaporation mechanism that occurs across a larger dryer. During
droplet solvent evaporation, a drug may have the opportunity to recrystallize during a small interval
of time when drug solubility reaches saturation in a solvent and when polymer viscosity is not
enough to stabilize the amorphous form of the drug [8]. Therefore, this qualifies the design and
operating mode of our miniaturized system compared to laboratory equipment. At this stage,
additional tests to investigate the physical stability and dissolution performance of the most promising
itraconazole–polymer combinations (e.g., made with Eudragit L100, HPMCP HP50, HPMCAS-LF, and
Eudragit L100-55) would enable the finetuning of the carrier selection.
Interestingly, the miscibility of itraconazole/Eudragit L100 produced at the screening scale was
improved up to 80% (w/w) DL compared to the respective ASD produced at the laboratory scale of
up to 60% (w/w) DL (Table 3). Although Tout was kept constant during the downscale approach,
this cannot predict the entire impact on powder properties regarding the changes in other CPPs like
drying and atomizing gas flow rate or inlet temperature [21,37]. As mentioned in the previous sections,
changes in process conditions and equipment design of the miniaturized system have been made
during downscaling, e.g., selection of atomization conditions and inlet temperature adapted to the
smaller drying chamber or the use of an appropriate powder collection system for small SDSD batches.
This has resulted in the collection of a fraction of spray-dried particles below the cyclone efficiency of
laboratory dryer (Figure 2), which may explain the improved miscibility obtained for screened ASD.
Due to the fact that smaller droplets are known to undergo a faster evaporation rate compared to larger
droplets, the window for phase separation is minimized and therefore a higher level of drug–polymer
mixing can be achieved [47]. Thus, the miscibility difference found for itraconazole/Eudragit L100
80-20 (w/w) produced at laboratory and screening scales is probably the result of the combined effects
of smaller droplet sizes generated from the nozzle, different drying kinetics/residence time within the
chamber, and improved selectivity of powder collection system.
3.3.3. Moisture and Residual Solvent Content of SDSDs
Finally, TGA analyses were performed on 40:60 (w/w) itraconazole ASDs and percentages of
weight loss recorded during experiments are summarized in Table 2. TGA experiments allow for the
rough estimation of the percentage of residual solvent and moisture content in spray-dried material.
Quantification of trace-level residual solvent can be performed using gas chromatography [36]. As seen
in Table 2, similar percentage of mass loss values were found for samples generated from the two
techniques. Solid dispersions that contain polymers such as PVPVA and PVPK30 display a higher
percentage of weight loss recorded during the heating process compared to other carriers. This can be
attributed to the inherent hygroscopicity of these carriers. More specifically, TGA results suggest that
solid dispersions produced at both scales contain a similar amount of solvent and moisture content.
This finding corroborates the similarities obtained regarding the phase behavior and thermal properties
of SDSDs at screening and laboratory scales, as illustrated in Figures 5 and 6. Because residual solvent
content acts as a plasticizing agent that disrupts drug-polymer interactions, decreases the Tg value of
amorphous system, and thus increases the molecular mobility, the physical and chemical stability of
the drug will be negatively impacted [48,49]. In this context, the proposed miniaturized equipment
offers an invaluable alternative to the standard screening approach, e.g., film casting, where the
residual solvent content is the major drawback of this methodology. Indeed, film-casted samples have
a generally relatively high solvent content that affects the performance of screened ASDs [50]. This
can generate false-negative results among screened drug-polymer combinations and hence falsify the
general outcome of the screening procedure [51].
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Table 3. Reproducibility of the miniaturized device (Min) to predict the phase behavior of itraconazole solid dispersions produced at laboratory scale (Lab) with Büchi
B290 at 20%, 40%, 60%, and 80% (w/w) DL. Green color used in the Table refers to the formation of glass solutions where amorphous drug is molecularly dispersed in
the carrier, orange color refers to the presence of residual crystallinity in the ASD or drug recrystallization process recorded during mDSC analysis.
ASDs HPMCP HP50 HPMCAS-LF PVPVA PVPK30 Soluplus Eudragit L100 Eudragit L100-55
DLScale Lab Min Lab Min Lab Min Lab Min Lab Min Lab Min Lab Min
20:40
(w/w) Glass solution Glass solution Glass solution
40:60
(w/w)
60:40
(w/w)
Glass solution Glass solution Glass solution Glass solution
80:20
(w/w)
Drug
melting/recryst.
Drug
melting/recryst.
Drug
melting/recryst.
Drug
melting/recryst.
Drug
melting/recryst. Drug
melt/recryst. GS.
Drug
melting/recryst.
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4. Conclusions
Our miniaturized system was found to consistently reproduce the properties of SDSDs produced
at the laboratory scale. Thus, the application of this novel device in pharmaceutical development
laboratories would help to guide scientists in the rational selection of adequate polymer and DL
selection for the development of SDSDs. This screening device would be invaluable in the early
stages of development when API availability and time for experimental work are scarce. An API
saving by a factor of 120 and a fourfold increased production rate per hour can be achieved with the
proposed system. The miniaturized system has been specially designed to operate with low volumes
of feed solution (0.25–1 mL) and was optimized for powder collection and ease of sample collection
for subsequent analytical characterization. The fact that the critical quality attributes of itraconazole
SDSDs widely translate to those manufactured at the laboratory scale in terms of morphology, PSD,
drug-polymer miscibility/solid state, and moisture/residual solvent content, qualifies the design,
operating mode, as well as the performance of our miniaturized screening device. This suggests the
ability of this small-scale equipment to reproduce the evaporation and particle formation processes that
occur at the laboratory scale. This is symbolized by the constant value of Tout throughout downscaling
approach that would ease the transfer from screening phases to laboratory productions. Based on this
positive correlation, future studies will focus on the investigation of reproducibility between the novel
device and a large-scale spray-dryer (kg scale) in terms of output parameters and particle/powder
attributes. Additionally, further work could focus on the possibility of leveraging Process Analytical
Technology (PAT) for the miniaturized screening device to measure droplets/particle characteristics
and heat/mass transfer online.
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